Mendoza, Abdel Azis .

HRN: 21-47-01  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/16/2022
AMPICILLIN 250MG (VIAL)
06/16/2022
06/16/2022
IVTT
85mg
Q12
Prematurity
Waiting Final Action 
06/16/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
06/16/2022
06/23/2022
IVTT
26mg
OD
Prematurity
Waiting Final Action 
06/16/2022
AMPICILLIN 250MG (VIAL)
06/16/2022
06/23/2022
IVTT
200mg
Q12
Prematurity
06/16/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
06/16/2022
06/23/2022
IVTT
20mg
OD
Prematurity
Waiting Final Action 
06/21/2022
CEFTAZIDIME 1GM (VIAL)
06/21/2022
06/27/2022
IVTT
85
Q12
Neonatal Sepsis
Waiting Final Action 
06/18/2023
CEFUROXIME 750MG (VIAL)
06/18/2023
06/25/2023
IV
260mg
Q8
Sepsis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: